¼¼°èÀÇ ´©³¶¿° ½ÃÀå
Dacryocystitis
»óǰÄÚµå : 1779899
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 374 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´©³¶¿° ½ÃÀåÀº 2030³â±îÁö 5,120¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 4,120¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ´©³¶¿° ½ÃÀåÀº 2024-2030³â¿¡ CAGR 3.7%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 5,120¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¿Ü°ú Ä¡·á´Â CAGR 4.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2,770¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾à¹° Ä¡·á ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 2.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1,120¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´©³¶¿° ½ÃÀåÀº 2024³â¿¡ 1,120¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 7.0%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 1,040¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.4%¿Í 2.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´©³¶¿° ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

´©³¶¿°ÀÌ ¾È°ú¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â?

´«¹°ÁÖ¸Ó´ÏÀÇ °¨¿°À̳ª ¿°ÁõÀÎ ´©³¶¿°Àº ³ó¾çÇü¼º, ½Ã·ÂÀå¾Ö µîÀÇ ÇÕº´Áõ °¡´É¼ºÀÌ ÀÖÀ¸¸ç, ¾È°ú¿¡¼­ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ´«¹°³¶¿°Àº ¼¼±Õ °¨¿°, ¿Ü»ó, ´«¹° ¹èÃ⠽ýºÅÛÀÇ Àå¾Ö·Î ÀÎÇØ ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ÅëÁõÀ» µ¿¹ÝÇÑ ºÎÁ¾, °úµµÇÑ ´«¹°, °í¸§ ¹èÃâÀ» À¯¹ßÇÕ´Ï´Ù. ´©³¶¿°À» Ä¡·áÇÏÁö ¾Ê°í ¹æÄ¡ÇÏ¸é ¾È¿ÍºÀ¿ÍÁ÷¿°À̳ª Àü½Å °¨¿°À¸·Î ÁøÇàµÉ ¼ö ÀÖÀ¸¸ç, Á¶±â Áø´Ü°ú Ä¡·á°¡ ÇʼöÀûÀÔ´Ï´Ù.

³ëÈ­¿¡ µû¸¥ ¾ÈÁúȯ, ½Å»ý¾ÆÀÇ ¼±Ãµ¼º ´©°ü Æó¼âÁõ, ¼ö¼ú ÈÄ ÇÕº´ÁõÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ´©³¶¿°ÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÄÜÅÃÆ®·»Áî »ç¿ëÀÚ¿Í ´«²¨Ç® ¼ºÇü¼ö¼úÀ» ¹Þ´Â »ç¶÷µéÀÌ Áõ°¡Çϸ鼭 ´©°ü °¨¿°ÀÇ À§Ç輺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½À ¼ö¼ú¹ý°ú Ç×»ýÁ¦ Ä¡·áÀÇ ¹ßÀüÀº ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±Çϰí È¿°úÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

´«¹°»ù¿° Ä¡·áÀÇ ÃֽŠÇõ½ÅÀº ¹«¾ùÀΰ¡?

´©³¶¿° Ä¡·á´Â ÷´Ü Ç×»ýÁ¦ Ä¡·á, ÃÖ¼Òħ½À ¼ö¼ú, »õ·Î¿î ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ µµÀÔÀ¸·Î ¹ßÀüÇØ ¿Ô½À´Ï´Ù. °¡Àå Áß¿äÇÑ ¹ßÀü Áß Çϳª´Â ³»½Ã°æÇÏ ´«¹°ÁÖ¸Ó´Ï ¼ºÇü¼ú(DCR)ÀÔ´Ï´Ù. ¿ÜºÎ¿¡¼­ Àý°³ÇÏÁö ¾Ê°í »õ·Î¿î ´«¹° ¹èÃâ °æ·Î¸¦ ¸¸µå´Â ÃÖ¼Òħ½ÀÀû ¼ö¼ú¹ýÀÔ´Ï´Ù. ÀÌ ½Ã¼úÀº ¸¸¼º ´©³¶¿°ÀÇ Ä¡·á¹ýÀ¸·Î ¼±È£µÇ°í ÀÖÀ¸¸ç, ÈäÅÍ Çü¼º°ú ȸº¹¿¡ ¼Ò¿äµÇ´Â ½Ã°£À» ÁÙ¿©ÁÖ´Â È¿°ú°¡ ÀÖ½À´Ï´Ù.

¶ÇÇÑ »ýºÐÇØ¼º ¾àÁ¦¿ëÃâ ½ºÅÙÆ®¸¦ »ç¿ëÇÏ¿© ´©°ü ÀçÆó»öÀ» ¹æÁöÇÏ°í °¨¿° À§ÇèÀ» °¨¼Ò½ÃÄÑ ¼ö¼ú ÈÄ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ³ª³ëÀÔÀÚ ±â¹ÝÀÇ Ç×»ýÁ¦ Á¡¾È¾×µµ ¾à¹°ÀÇ Ä§Åõ¼ºÀ» ³ôÀ̰í Ç×±Õ È°¼ºÀ» ¿À·¡ Áö¼Ó½Ã۱â À§ÇØ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ´ÙÅ©¶óÀÌ¿À ½ÅƼ±×·¡ÇÇ, ÃÊÀ½ÆÄ °Ë»ç µî AI¸¦ Ȱ¿ëÇÑ Áø´Ü Åø¿Í ¿µ»ó ±â¼úÀº ´«¹°³¶¿°ÀÇ Á¶±â ¹ß°ß°ú °³º° Ä¡·á¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

½ÃÀå µ¿Çâ°ú ±ÔÁ¦ °¡À̵å¶óÀÎÀÌ ´«¹°»ù¿° Ä¡·á¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

Àúħ½ÀÀû ¾È°ú ¼ö¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ°í °í±Þ Ç×±Õ ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ´«¹°³¶¿° Ä¡·áÀÇ Àü¸ÁÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. °³¹ßµµ»ó±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë´Â ¾È°ú ÀÇ·á ¼­ºñ½º Á¢±Ù¼ºÀ» °³¼±Çϰí, ´©°ü °¨¿°ÀÇ Á¶±â Áø´Ü ¹× Ä¡·á¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³ëÀÎ Àα¸ Áõ°¡¿Í ¸¸¼º ¿°Áõ¼º ¾ÈÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ FDA, À¯·´ÀǾàǰû(European Medicines Agency) µî ±ÔÁ¦±â°üÀº ¾È°ú¿ë ÀǾàǰÀÇ Á¦Á¦ ¹× Ä¡·á¿¡ »ç¿ëµÇ´Â ÀÇ·á±â±â¿¡ ¾ö°ÝÇÑ °¡À̵å¶óÀÎÀ» Àû¿ëÇϰí ÀÖ½À´Ï´Ù. Ç×»ýÁ¦ Á¡¾ÈÁ¦, ½ºÅÙÆ®, ¼ö¼ú±â±¸¸¦ °³¹ßÇÏ´Â Á¦Á¶¾÷ü´Â ¹«±Õ ¹× »ýü ÀûÇÕ¼º ±âÁØÀ» ÁؼöÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀÇ ¹ßÀüÀº ´«¹°³¶¿° ȯÀÚÀÇ ¿ø°Ý Áø·á¿Í ó¹æ °ü¸®¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

´«¹°»ù¿° ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

¾È°ú ¼ö¼úÀÇ ¹ßÀü, Ç×»ýÁ¦ ³»¼º °¨¿° Áõ°¡, ¾È°ú ÁúȯÀÇ Á¶±â °ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ´«¹°³¶¿° ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ³»½Ã°æÀû DCR°ú ºñħ½ÀÀû ¾à¹°Àü´Þ½Ã½ºÅÛÀÇ Ã¤ÅÃÀ¸·Î ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á ¼ºÀûÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµÀÇ È®´ëµµ Áß¿äÇÑ ¿äÀÎÀ¸·Î ¼Ò¾Æ ¾È°ú, ¼ö¼ú ÈÄ ¾È°ú ÀÇ·á, ³ëÀÎ ÀÇ·á¿¡¼­ ´©³¶¿° Ä¡·á°¡ Áß¿ä½ÃµÇ°í ÀÖ½À´Ï´Ù. ¾È°ú Áø´Ü¿¡ AI¿Í ¸Ó½Å·¯´×À» ÅëÇÕÇÏ¿© ´©°ü Æò°¡ÀÇ Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚº° Ç×»ýÁ¦ ¿ä¹ý, ¸ÂÃãÇü ¼ö¼ú¹ý µî °³Àκ° ¸ÂÃã Ä¡·á Á¢±Ù¹ýÀÇ °³¹ßÀº ´«¹°³¶¿° °ü¸®ÀÇ ¹Ì·¡¸¦ ¸¸µé¾î°¡°í ÀÖ½À´Ï´Ù. ¾È°ú ¿¬±¸°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ´«¹°³¶¿° ½ÃÀåÀº ²ÙÁØÈ÷ ¼ºÀåÇÏ°í ¾È±¸ °¨¿° Ä¡·á ¹× ¼ö¼ú Ä¡·áÀÇ Çõ½ÅÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(¿Ü°ú Ä¡·á, Åõ¾à Ä¡·á), ÀûÀÀÁõ(¸¸¼º ´©³¶¿° Ä¡·á, ±Þ¼º ´©³¶¿° Ä¡·á, ¼±Ãµ¼º ´©³¶¿° Ä¡·á), ÆÇ¸Åä³Î(±â°ü ÆÇ¸Åä³Î, ¼Ò¸Å ÆÇ¸Åä³Î)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Dacryocystitis Market to Reach US$51.2 Million by 2030

The global market for Dacryocystitis estimated at US$41.2 Million in the year 2024, is expected to reach US$51.2 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Surgical Treatment, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$27.7 Million by the end of the analysis period. Growth in the Medication Treatment segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.2 Million While China is Forecast to Grow at 7.0% CAGR

The Dacryocystitis market in the U.S. is estimated at US$11.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.4 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Dacryocystitis Market - Key Trends & Growth Drivers Summarized

Why Is Dacryocystitis Becoming a Growing Concern in Ophthalmology?

Dacryocystitis, an infection or inflammation of the lacrimal sac, is becoming an increasing concern in ophthalmology due to its potential complications, including abscess formation and vision impairment. The condition is often caused by bacterial infections, trauma, or obstructions in the tear drainage system, leading to painful swelling, excessive tearing, and pus discharge. If left untreated, dacryocystitis can progress to orbital cellulitis or systemic infections, making early diagnosis and treatment essential.

The rising prevalence of age-related eye disorders, congenital tear duct obstructions in newborns, and post-surgical complications has increased the incidence of dacryocystitis. Additionally, the growing number of contact lens users and individuals undergoing aesthetic eyelid surgeries has contributed to a higher risk of tear duct infections. Advancements in minimally invasive surgical techniques and antibiotic therapies are improving patient outcomes, driving demand for effective treatment solutions.

What Are the Latest Innovations in Dacryocystitis Treatment?

The treatment of dacryocystitis has evolved with the introduction of advanced antibiotic therapies, minimally invasive procedures, and novel drug delivery systems. One of the most significant advancements is endoscopic dacryocystorhinostomy (DCR), a minimally invasive surgical procedure that creates a new tear drainage pathway without external incisions. This technique has become the preferred treatment for chronic dacryocystitis, reducing scarring and recovery time.

Additionally, the use of biodegradable drug-eluting stents is improving post-surgical outcomes by preventing tear duct re-blockage and reducing infection risks. Nanoparticle-based antibiotic eye drops are also being developed to enhance drug penetration and prolong antibacterial activity. AI-driven diagnostic tools and imaging techniques, such as dacryoscintigraphy and ultrasonography, are aiding in the early detection and personalized treatment of dacryocystitis.

How Are Market Trends and Regulatory Guidelines Influencing Dacryocystitis Treatment?

The increasing adoption of minimally invasive ophthalmic surgeries and the demand for advanced antimicrobial therapies are shaping the dacryocystitis treatment landscape. The expansion of healthcare infrastructure in developing regions has improved access to eye care services, facilitating early diagnosis and treatment of tear duct infections. Additionally, the rising geriatric population and the growing prevalence of chronic inflammatory eye conditions are fueling market demand.

Regulatory agencies, such as the U.S. FDA and the European Medicines Agency, are enforcing strict guidelines on ophthalmic drug formulations and medical devices used in dacryocystitis treatment. Compliance with sterility and biocompatibility standards is crucial for manufacturers developing antibiotic eye drops, stents, and surgical instruments. Additionally, the trend toward telemedicine and digital health platforms is enabling remote consultation and prescription management for dacryocystitis patients.

What Is Driving the Growth of the Dacryocystitis Market?

The growth in the dacryocystitis market is driven by advancements in ophthalmic surgery, increasing antibiotic-resistant infections, and rising awareness of early eye disease management. The adoption of endoscopic DCR and non-invasive drug delivery systems is improving treatment outcomes while minimizing complications.

End-use expansion is another critical factor, with dacryocystitis treatment becoming a focus in pediatric ophthalmology, post-surgical eye care, and geriatric medicine. The integration of AI and machine learning in ophthalmic diagnostics is also enhancing the accuracy of tear duct assessments. Additionally, the development of personalized treatment approaches, including patient-specific antibiotic regimens and customized surgical techniques, is shaping the future of dacryocystitis management. As ophthalmic research continues to advance, the dacryocystitis market is expected to grow steadily, supporting innovations in eye infection treatment and surgical care.

SCOPE OF STUDY:

The report analyzes the Dacryocystitis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Surgical Treatment, Medication Treatment); Indication (Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment, Congenital Dacryocystitis Treatment); Sales Channel (Institutional Sales Channel, Retail Sales Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â